ArticleThe Journal of biological chemistry2011
Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3.
Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Recombinant G-CSF-ApoAI Fusion Protein Is a Pleiotropic Factor.Molecules (Basel, Switzerland) · 2025Article
- Synergistic Anti-Inflammatory Activity of Lipid-Free Apolipoprotein (apo) A-I and CIGB-258 in Acute-Phase Zebrafish via Stabilization of the apoA-I Structure to Enhance Anti-Glycation and Antioxidant Activities.International journal of molecular sciences · 2024Article
- Anti-inflammatory mechanism of Apolipoprotein A-I.Frontiers in immunology · 2024Review
- High-Density Lipoproteins: A Role in Inflammation in COPD.International journal of molecular sciences · 2022Review
- Comparative Whey Proteome Profiling of Donkey Milk With Human and Cow Milk.Frontiers in nutrition · 2022Article
- APOA1 Level is Negatively Correlated with the Severity of COVID-19.International journal of general medicine · 2022Article
- Serum apolipoprotein A-I potentiates the therapeutic efficacy of lysocin E against Staphylococcus aureus.Nature communications · 2021Article
- High-density lipoprotein-mediated cardioprotection in heart failure.Heart failure reviews · 2021Review
- Quantitative Label-Free Proteomic Analysis of Milk Fat Globule Membrane in Donkey and Human Milk.Frontiers in nutrition · 2021Article
- Post-Translational Protein Deimination Signatures in Serum and Serum-Extracellular Vesicles ofInternational journal of molecular sciences · 2020Article
- Deimination Protein Profiles inFrontiers in immunology · 2020Article
- Article
- Review
- Extracellular small non-coding RNA contaminants in fetal bovine serum and serum-free media.Scientific reports · 2019Article
- Role of apolipoproteins, ABCA1 and LCAT in the biogenesis of normal and aberrant high density lipoproteins.Journal of biomedical research · 2017Article
- Peptides from American alligator plasma are antimicrobial against multi-drug resistant bacterial pathogens including Acinetobacter baumannii.BMC microbiology · 2016Article
- High-Density Lipoprotein Binds to Mycobacterium avium and Affects the Infection of THP-1 Macrophages.Journal of lipids · 2016Article
- Proliferation and resistance difference of a liver-parasitized myxosporean in two different gynogenetic clones of gibel carp.Parasitology research · 2014Article
- Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL.Journal of lipid research · 2013Article
- Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL.Journal of lipid research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 3 countries.
Funding
Abstract
Apolipoprotein A-I (apoA-I), the main protein component of high density lipoprotein (HDL), is well recognized for its antiatherogenic, antioxidant, and antiinflammatory properties. Here, we report a novel role for apoA-I as a host defense molecule that contributes to the complement-mediated killing of an important gastrointestinal pathogen, Gram-negative bacterium Yersinia enterocolitica. We specifically show that the C-terminal domain of apoA-I is the effector site providing the bactericidal activity. Although the presence of the lipopolysaccharide O-antigen on the bacterial surface is absolutely required for apoA-I to kill the bacteria, apoA-I does not interact with the bacteria directly. To the contrary, exposure of the bacteria by serum proteins triggers apoA-I deposition on the bacterial surface. As our data show that both purified lipid-free and HDL-associated apoA-I displays anti-bacterial potential, apoA-I mimetic peptides may be a promising therapeutic agent for the treatment of certain Gram-negative infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.